10.23

5.68% +0.55

Pre-market: 11.37 1.14 +11.14%

Precision Biosciences Inc (DTIL)

Overview News Price History Option Chain Discussions Forecast

Precision Biosciences Inc stock is currently priced at $10.23, with a 24-hour trading volume of 31,105. It has seen a +5.68% increased in the last 24 hours and a -11.96% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $9.56 pivot point. If it approaches the $10.26 resistance level, significant changes may occur.

Previous Close:

$9.68

Open:

$9.67

24h Volume:

31,105

Market Cap:

$70.75M

Revenue:

$52.29M

Net Income/Loss:

$-73.52M

P/E Ratio:

-12.63

EPS:

-0.81

Net Cash Flow:

$-100.45M

1W Performance:

-20.51%

1M Performance:

-11.96%

6M Performance:

+3,342%

1Y Performance:

+1,024%

1D Range:

$9.52

$10.36

52W Range:

$0.275

$19.43

Precision Biosciences Inc Stock (DTIL) Company Profile

Name

Precision Biosciences Inc

Sector

Healthcare (1196)

Industry

Biotechnology (685)

Phone

919-314-5512

Address

Dibrell Building, Suite A-100 302 East Pettigrew Street, Durham, NC

Employee

146

Twitter

@PrecisionBioSci

Next Earnings Date

2024-05-07

Latest SEC Filings

DTIL's Discussions on Twitter

Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-17-22	Initiated	BMO Capital Markets	Outperform
Jun-09-22	Downgrade	William Blair	Outperform → Mkt Perform
Jul-27-20	Resumed	BTIG Research	Buy
Apr-03-20	Downgrade	Goldman	Buy → Neutral
Mar-05-20	Initiated	Stifel	Buy
Feb-25-20	Initiated	William Blair	Outperform
Aug-09-19	Initiated	BTIG Research	Buy
Jul-16-19	Initiated	H.C. Wainwright	Buy
Apr-22-19	Initiated	Barclays	Overweight
Apr-22-19	Initiated	Goldman	Buy
Apr-22-19	Initiated	JP Morgan	Overweight
Apr-22-19	Initiated	Jefferies	Buy

View All

Precision Biosciences Inc Stock (DTIL) Latest News

Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?

Zacks Investment Research

Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?

Zacks Investment Research

Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know

Zacks Investment Research

Precision Biosciences Inc Stock (DTIL) Financials Data

Precision Biosciences Inc (DTIL) Revenue 2024

DTIL reported a revenue (TTM) of $52.29 million for the quarter ending September 30, 2023, a +150.91% rise year-over-year.

Precision Biosciences Inc (DTIL) Net Income 2024

DTIL net income (TTM) was -$73.52 million for the quarter ending September 30, 2023, a +30.27% increase year-over-year.

Precision Biosciences Inc (DTIL) Cash Flow 2024

DTIL recorded a free cash flow (TTM) of -$100.45 million for the quarter ending September 30, 2023, a -93.98% decrease year-over-year.

Precision Biosciences Inc (DTIL) Earnings per Share 2024

DTIL earnings per share (TTM) was -$0.66 for the quarter ending September 30, 2023, a +56.58% growth year-over-year.

Precision Biosciences Inc Stock (DTIL) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Amoroso Michael	President and CEO	Jan 22 '24	Sale	0.36	137,390	49,460	356,433
List Alan	Chief Medical Officer	Jan 22 '24	Sale	0.36	21,526	7,749	94,982
Scimeca Dario	General Counsel and Secretary	Jan 22 '24	Sale	0.36	21,287	7,663	151,028
Amoroso Michael	President and CEO	Nov 03 '23	Sale	0.40	125,025	50,010	227,103
Scimeca Dario	General Counsel and Secretary	Nov 03 '23	Sale	0.40	16,023	6,409	112,970
Scimeca Dario	General Counsel and Secretary	Jun 08 '23	Sale	0.75	13,361	10,021	68,473
List Alan	Chief Medical Officer	Apr 27 '23	Sale	0.79	7,771	6,139	56,496

Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.